PRME (Prime Medicine, Inc. Common Stock) Stock Analysis - Politician Trades

Prime Medicine, Inc. Common Stock (PRME) is a publicly traded Healthcare sector company. As of May 21, 2026, PRME trades at $2.81 with a market cap of $507.54M and a P/E ratio of -2.08. PRME moved +0.00% today. Year to date, PRME is -20.73%; over the trailing twelve months it is +140.85%. Its 52-week range spans $1.11 to $6.94. Analyst consensus is strong buy with an average price target of $7.80. Rallies surfaces PRME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded PRME stock?

Rallies tracks politician and congressional stock disclosures for PRME, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

PRME Key Metrics

Key financial metrics for PRME
MetricValue
Price$2.81
Market Cap$507.54M
P/E Ratio-2.08
EPS$-1.35
Dividend Yield0.80%
52-Week High$6.94
52-Week Low$1.11
Volume79.85K
Avg Volume0
Revenue (TTM)$4.63M
Net Income$-201.14M
Gross Margin0.00%

Latest PRME News

Recent PRME Insider Trades

  • GV 2021 GP, L.L.C. bought 1.50M (~$4.95M) on Aug 1, 2025.
  • NELSEN ROBERT bought 3.03M (~$10.00M) on Aug 1, 2025.
  • ARCH Venture Partners XII, LLC bought 3.03M (~$10.00M) on Aug 1, 2025.

PRME Analyst Consensus

8 analysts cover PRME: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.80.

Common questions about PRME

Which politicians traded PRME stock?
Rallies tracks politician and congressional stock disclosures for PRME, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in PRME?
Yes. Rallies tracks politician and congressional stock disclosures for PRME, including reported purchases, sales, dates, owners, and trade amounts when available.
Is PRME research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PRME. It does not provide personalized investment advice.
PRME

PRME